AU2019297522B2 - Multi-specific Wnt surrogate molecules and uses thereof - Google Patents

Multi-specific Wnt surrogate molecules and uses thereof

Info

Publication number
AU2019297522B2
AU2019297522B2 AU2019297522A AU2019297522A AU2019297522B2 AU 2019297522 B2 AU2019297522 B2 AU 2019297522B2 AU 2019297522 A AU2019297522 A AU 2019297522A AU 2019297522 A AU2019297522 A AU 2019297522A AU 2019297522 B2 AU2019297522 B2 AU 2019297522B2
Authority
AU
Australia
Prior art keywords
fzd
binding
lrp6e3e4
fzd8
aasslqs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019297522A
Other languages
English (en)
Other versions
AU2019297522A1 (en
Inventor
Yang Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Surrozen Operating Inc
Original Assignee
Surrozen Operating Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69059929&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2019297522(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Surrozen Operating Inc filed Critical Surrozen Operating Inc
Publication of AU2019297522A1 publication Critical patent/AU2019297522A1/en
Assigned to Surrozen Operating, Inc. reassignment Surrozen Operating, Inc. Amend patent request/document other than specification (104) Assignors: SURROZEN, INC.
Application granted granted Critical
Publication of AU2019297522B2 publication Critical patent/AU2019297522B2/en
Priority to AU2026206257A priority Critical patent/AU2026206257A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2019297522A 2018-07-05 2019-07-05 Multi-specific Wnt surrogate molecules and uses thereof Active AU2019297522B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026206257A AU2026206257A1 (en) 2018-07-05 2026-07-20 Multi-specific Wnt surrogate molecules and uses thereof

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862694339P 2018-07-05 2018-07-05
US62/694,339 2018-07-05
US201862782122P 2018-12-19 2018-12-19
US62/782,122 2018-12-19
US201962797772P 2019-01-28 2019-01-28
US62/797,772 2019-01-28
PCT/US2019/040687 WO2020010308A1 (en) 2018-07-05 2019-07-05 Multi-specific wnt surrogate molecules and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026206257A Division AU2026206257A1 (en) 2018-07-05 2026-07-20 Multi-specific Wnt surrogate molecules and uses thereof

Publications (2)

Publication Number Publication Date
AU2019297522A1 AU2019297522A1 (en) 2021-01-28
AU2019297522B2 true AU2019297522B2 (en) 2026-04-23

Family

ID=69059929

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019297522A Active AU2019297522B2 (en) 2018-07-05 2019-07-05 Multi-specific Wnt surrogate molecules and uses thereof
AU2026206257A Pending AU2026206257A1 (en) 2018-07-05 2026-07-20 Multi-specific Wnt surrogate molecules and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026206257A Pending AU2026206257A1 (en) 2018-07-05 2026-07-20 Multi-specific Wnt surrogate molecules and uses thereof

Country Status (10)

Country Link
US (1) US20210292422A1 (enExample)
EP (2) EP3820906B1 (enExample)
JP (2) JP2021529796A (enExample)
CN (2) CN120623353A (enExample)
AU (2) AU2019297522B2 (enExample)
CA (1) CA3104526A1 (enExample)
DK (1) DK3820906T3 (enExample)
ES (1) ES3058239T3 (enExample)
PL (1) PL3820906T3 (enExample)
WO (1) WO2020010308A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018211985B2 (en) 2017-01-26 2025-02-13 Surrozen Operating, Inc. Tissue-specific Wnt signal enhancing molecules and uses thereof
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
JP7418332B2 (ja) * 2017-12-19 2024-01-19 スロゼン オペレーティング， インコーポレイテッド 抗フリズルド抗体及び使用方法
CN118271444A (zh) * 2017-12-19 2024-07-02 瑟罗泽恩奥普瑞汀公司 Wnt替代分子和其用途
US20210032352A1 (en) * 2018-02-14 2021-02-04 Antera Therapeutics Inc. Multivalent Binding Molecules Activating WNT Signaling and Uses Thereof
JP2021530223A (ja) 2018-07-09 2021-11-11 スロゼン， インコーポレイテッド 組織特異性Ｗｎｔシグナル増強分子及びその使用
CA3144499A1 (en) * 2019-07-02 2021-01-07 Surrozen Operating, Inc. Monospecific anti-frizzled antibodies and methods of use
US20230138045A1 (en) * 2020-02-24 2023-05-04 Surrozen Operating, Inc. Wnt super agonists
WO2022104280A1 (en) 2020-11-16 2022-05-19 Surrozen Operating, Inc. Liver-specific wnt signal enhancing molecules and uses thereof
CA3204321A1 (en) 2020-12-18 2022-06-23 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
WO2023250402A2 (en) * 2022-06-22 2023-12-28 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
CR20240266A (es) * 2021-12-31 2024-11-11 Surrozen Operating Inc Compuesto específico de receptor wnt y método relacionado con este
AU2024279826A1 (en) * 2023-05-29 2026-01-08 Surrozen Operating, Inc. Wnt surrogate agents and methods for lacrimal gland regeneration
WO2026044275A1 (en) * 2024-08-23 2026-02-26 Surrozen Operating, Inc. Wnt surrogate fusion molecule
WO2026044274A1 (en) * 2024-08-23 2026-02-26 Surrozen Operating, Inc. Wnt surrogate fusion molecule

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015063187A1 (en) * 2013-10-30 2015-05-07 Sergej Michailovic Kiprijanov Multivalent antigen-binding proteins
US20170218078A1 (en) * 2016-02-03 2017-08-03 Amgen Research (Munich) Gmbh Bispecific t cell engaging antibody constructs
US20170306029A1 (en) * 2014-09-12 2017-10-26 The Board Of Trustees Of The Leland Stanford Junior University Wnt signaling agonist molecules
WO2019126398A1 (en) * 2017-12-19 2019-06-27 Surrozen, Inc. Wnt surrogate molecules and uses thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US20030044409A1 (en) 2001-05-01 2003-03-06 Carson Dennis A. Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP2007512846A (ja) 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
BRPI0514068B8 (pt) 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
DE102004050620A1 (de) 2004-10-13 2006-04-20 Eberhard-Karls-Universität Tübingen Monoklonaler Antikörper gegen Frizzled-Rezeptoren
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
JP2008528010A (ja) 2005-01-31 2008-07-31 アブリンクス ナームローゼ フェンノートシャップ 重鎖抗体の可変ドメイン配列を作出する方法
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
DE102005035568A1 (de) 2005-07-25 2007-02-01 M-Phasys Gmbh Frizzled 9 als Biomarker für Substrukturen des humanen Gehirns
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
US8221751B2 (en) 2006-06-21 2012-07-17 Oncotherapy Science, Inc. Tumor-targeting monoclonal antibodies to FZD10 and uses thereof
MX2010004761A (es) * 2007-11-02 2010-05-19 Novartis Ag Moleculas y metodos para modular la proteina relacionada con el receptor de lipoproteina de baja densidad 6 (lrp6).
EP3211011A1 (en) 2007-11-16 2017-08-30 Nuvelo, Inc. Antibodies to lrp6
EP2331136B1 (en) 2008-09-26 2018-01-10 OncoMed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
US8642339B2 (en) 2009-02-03 2014-02-04 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
KR101899835B1 (ko) 2010-03-24 2018-09-19 제넨테크, 인크. 항-ｌｒｐ６ 항체
CN102971337B (zh) 2010-04-01 2016-09-21 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
AU2014306564B2 (en) 2013-08-14 2019-10-17 Antlera Therapeutics Inc. Antibodies against frizzled proteins and methods of use thereof
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
WO2016205566A1 (en) 2015-06-16 2016-12-22 The Regents Of The University Of California Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
WO2016205551A2 (en) 2015-06-16 2016-12-22 The Regents Of The University Of California Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
PT3383425T (pt) * 2015-12-04 2020-10-07 Boehringer Ingelheim Int Polipéptidos biparatópicos que antagonizam a sinalização wnt em células tumorais
WO2017127933A1 (en) 2016-01-29 2017-08-03 The Governing Council Of The University Of Toronto Frizzled protein-binding agents and methods of use thereof
JP7014724B2 (ja) 2016-02-06 2022-02-01 エピムアブ バイオセラピューティクス インコーポレイテッド タンデム型Ｆａｂ免疫グロブリンおよびその使用
US20210032352A1 (en) * 2018-02-14 2021-02-04 Antera Therapeutics Inc. Multivalent Binding Molecules Activating WNT Signaling and Uses Thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015063187A1 (en) * 2013-10-30 2015-05-07 Sergej Michailovic Kiprijanov Multivalent antigen-binding proteins
US20170306029A1 (en) * 2014-09-12 2017-10-26 The Board Of Trustees Of The Leland Stanford Junior University Wnt signaling agonist molecules
US20170218078A1 (en) * 2016-02-03 2017-08-03 Amgen Research (Munich) Gmbh Bispecific t cell engaging antibody constructs
WO2019126398A1 (en) * 2017-12-19 2019-06-27 Surrozen, Inc. Wnt surrogate molecules and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Janda, C. et al., 'Structural Basis of Wnt Recognition by Frizzled', Science, (2012-07-06), vol. 337, no. 6090, pages 59 - 64, doi: 10.1126/science.1222879. *

Also Published As

Publication number Publication date
CA3104526A1 (en) 2020-01-09
EP3820906A4 (en) 2022-04-20
EP4733325A2 (en) 2026-04-29
WO2020010308A1 (en) 2020-01-09
JP2021529796A (ja) 2021-11-04
CN120623353A (zh) 2025-09-12
EP4733325A3 (en) 2026-05-13
JP2024001292A (ja) 2024-01-09
AU2019297522A1 (en) 2021-01-28
CN112566940B (zh) 2025-06-13
ES3058239T3 (en) 2026-03-09
AU2026206257A1 (en) 2026-08-13
CN112566940A (zh) 2021-03-26
EP3820906B1 (en) 2025-10-15
DK3820906T3 (da) 2025-12-15
US20210292422A1 (en) 2021-09-23
PL3820906T3 (pl) 2026-04-13
EP3820906A1 (en) 2021-05-19

Similar Documents

Publication Publication Date Title
EP3820906B1 (en) Multi-specific wnt surrogate molecules and uses thereof
AU2018393073B2 (en) Wnt surrogate molecules and uses thereof
JP7667823B2 (ja) 抗ｌｒｐ５／６抗体及び使用方法
US12606629B2 (en) Monospecific anti-frizzled antibodies and methods of use
WO2019126399A1 (en) Anti-frizzled antibodies and methods of use
CN115427446A (zh) Wnt超级激动剂
US20240262918A1 (en) Fc-modified wnt surrogate molecules and uses thereof
WO2026044275A1 (en) Wnt surrogate fusion molecule
WO2026044271A1 (en) Wnt surrogate fusion molecule
WO2026044274A1 (en) Wnt surrogate fusion molecule

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: SURROZEN OPERATING, INC.

Free format text: FORMER NAME(S): SURROZEN, INC.

CB Opposition filed

Opponent name: MERCK SHARP & DOHME LLC